Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7145
Reference
MSAN(2020)108
Name
H2-antagonists (cimetidine, famotidine and nizatidine): level 2: update
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
SUPPLIES
Description
Suppliers of cimetidine tablets, famotidine tablets and nizatidine capsules have advised of changes to the availability of the following preparations:
Famotidine 20mg, 40mg tablets
Cimetidine 200mg, 400mg tablets
Cimetidine 800mg tablets
Cimetidine 200mg/5ml oral solution
Nizatidine 150mg, 300mg capsules.
Contact Name
Contact Email
Contact Address
Created
2020-11-09 00:00:00
Click to go back to homepage